Login to Your Account

Other News To Note

Wednesday, August 31, 2011
KemPharm Inc., of North Liberty, Iowa, will initiate development of its attention deficit hyperactivity disorder (ADHD) candidate KP415. It will apply the PharmFilm technology to the drug in order to create an appropriate dosage form for ADHD. In preclinical trials, it showed the potential to have an improved side effect profile compared to methylphenidate drugs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription